| Identification | Back Directory | [Name]
Gatifloxacinacid | [CAS]
121577-32-0 | [Synonyms]
Gatifloxacinacid
AM 1155 hydrochloride
PD 135432 hydrochloride)
BMS-206584 (hydrochloride)
BMS 206584-01 hydrochloride
Gatifloxacin hydrochloride
(AM 1155 hydrochloride
AM 1155 HYDROCHLORIDE;BMS 206584-01 HYDROCHLORIDE;PD 135432 HYDROCHLORIDE
3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(3-Methyl-1-piperazinyl)-4-oxo-,hydrochloride (1:1)
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(3-Methyl-1-piperazinyl)-4-oxo-, Monohydrochloride (9CI) | [Molecular Formula]
C19H22FN3O4.ClH | [MOL File]
121577-32-0.mol | [Molecular Weight]
411.859 |
| Hazard Information | Back Directory | [Uses]
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo. | [Biological Activity]
Gatifloxacin hydrochloride (AM-1155 hydrochloride) is a potent fluoroquinolone antibiotic with broad-spectrum antimicrobial activity. | [in vivo]
Gatifloxacin hydrochloride (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with Nocardia brasiliensis . < p> | Animal Model: | Female BALB/c mice with Nocardia brasiliensis in the right hind footpad | | Dosage: | 100 mg/kg | | Administration: | Subcutaneous injection; 3 times a day; 30 days | | Result: | Reduced the production of lesions in mice. | | [target]
| Topoisomerase II 36.7 μM () | | [IC 50]
Quinolone; Topoisomerase II: 36.7 μM () | [storage]
Store at -20°C | [References]
[1] Takei M, et al. Inhibitory activities of Gatifloxacin hydrochloride (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Antimicrob Agents Chemother.?1998 Oct;42(10):2678-81. DOI:10.1128/AAC.42.10.2678
[2] Fukuda H, et al. Antibacterial activity of Gatifloxacin hydrochloride (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother.?1998 Aug;42(8):1917-22. DOI:10.1128/AAC.42.8.1917
[3] Yamada C, et al. Gatifloxacin hydrochloride?acutely?stimulates?insulin?secretion?and?chronically?suppresses?insulin?biosynthesis. Eur J Pharmacol.?2006 Dec 28;553(1-3):67-72. Epub 2006 Sep 28. DOI:10.1016/j.ejphar.2006.09.043
[4] Daw-Garza A, et al. In?vivo?therapeutic?effect?of?Gatifloxacin mesylate?on?BALB/c?mice?infected?with?Nocardia?brasiliensis.Antimicrob Agents Chemother.?2008 Apr;52(4):1549-50. DOI:10.1128/AAC.00148-08 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|